acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid

Clicks: 118
ID: 244052
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #52 of 54 articles by views in proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Radioactive iodine (RAI) therapy plays an important role in the management of thyroid malignancies. Leukemia is a very rare complication of radioactive therapy. There are very few case reports with doses below 100 mCi causing leukemia. We report a case of papillary carcinoma of the thyroid treated with 80 mCi RAI who later developed acute myeloid leukemia. Thus, all patients with thyroid carcinoma treated with RAI should undergo periodic hematological examinations irrespective of RAI dose.
Reference Key
ankit2009turkishacute Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Jain Ankit;Premalata CS;Saini KV;Bapsy PP;Sajeevan KV;Tejinder Singh;Ullas Batra;Babu Govind;Lokanatha Dasappa;Suresh Atilli;Permeshwar R
Journal proceedings of the international conference on iot in social, mobile, analytics and cloud, i-smac 2017
Year 2009
DOI
DOI not found
URL
http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-07279
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.